Skip to content

ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy

11 May 2022

Paris and Lyon, May 11, 2022 – ORPHELIA Pharma, the French biopharmaceutical company dedicated to the development and commercialization of pediatric drugs in the fields of oncology and neurology, announces today that it has obtained a one million Euro grant from Bpifrance to develop a therapy to treat a rare epileptic encephalopathy in children.

We collaborate actively with academic teams on this program, the clinical development of which could begin within 2 years,” comments Jeremy Bastid, Chief Development Officer of ORPHELIA Pharma. “This is an ambitious project for which we have a strong scientific rationale and that could improve the care of these patients“, he adds.

We would like to thank the Bpifrance teams for their renewed support, which has enabled us to initiate the development of a drug which could become a new therapeutic option in this orphan indication,” concludes Hugues Bienaymé, General Manager.

About ORPHELIA Pharma

ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of paediatric and orphan diseases. ORPHELIA Pharma’s mission is to provide patients with essential hospital products in the fields of neurology and oncology, with formulations adapted to the paediatric population. With two medicines approved in the European Union and one product in an advanced phase of clinical development, ORPHELIA Pharma has recently set up regional agreements in the European Union, the USA and China and is carrying out research projects through academic and industrial partnerships.